Agenus Inc (AGEN)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$6.97+4.50%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
Research Workspace
Put AGEN beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Achieve positive net income: Comparison needs review.
View ThesisRevenue growth is accelerating — up about 30% over the past year.
View GrowthMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is highly volatile — it swings about 3% on a typical day and fell roughly 41% in its worst 12-month stretch.
View RiskAgenus's BOT+BAL clinical progress must keep compounding to justify the price. Recent trial results strongly reinforce the development path. The stock trades at 2.1 times sales versus an 8.9 times peer median. Expectations look modest compared to our internal view. Our model puts the next-quarter miss probability near 65%. The thesis comparison is not yet verified. Peer multiples imply a price about 84% above where it trades. The thesis is on watch. This read is provisional.
Trailing returns as of 2026-11-04. AGEN is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 3 analysts currently covering AGEN (as of Nov 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare AGEN with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| AGEN Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 2 valuation methods, at three horizons. As of 2026-11-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put AGEN next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Maintain disciplined capital allocation and strengthen balance sheet
Earnings beat supports disciplined capital allocation thesis.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-11-04. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Advances: Advance BOT+BAL clinical development and regulatory approval
Positive trial results support BOT+BAL development and approval.
Advances: Prioritize neoadjuvant BOT+BAL development in MSS colon cancer
Neoadjuvant focus aligns with growth strategy in MSS colon cancer.
Advances: Maintain disciplined capital allocation and strengthen balance sheet
Loan extension supports capital allocation and balance sheet strength.
Threatens: Maintain disciplined capital allocation and strengthen balance sheet
Analysts' rework affects capital allocation and balance sheet outlook.
Threatens: Maintain disciplined capital allocation and strengthen balance sheet
Higher costs may hinder capital allocation objectives.
Advances: Increase revenue
Positive Phase 1b data suggests potential for increased revenue.
Acceptance at ESMO boosts credibility for Agenus' cancer drug.
